We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




New Reagent Aids in Diagnosis of Connective Tissue Disease in Hard-to-Detect Autoimmune Conditions

By LabMedica International staff writers
Posted on 19 Oct 2023

The increasing incidence of autoimmune diseases like rheumatoid arthritis, lupus, and multiple sclerosis has created great demand for accurate and reliable diagnostic methods. More...

As patients become more knowledgeable about the symptoms and risks of these diseases, they are seeking quicker testing solutions for early detection and management. Reagents and consumables are a key component in the diagnostic process of autoimmune disorders. Now, a new reagent can aid in the diagnosis of connective tissue disease in hard-to-diagnose autoimmune diseases, thus speeding up diagnosis and enhancing patient outcomes.

Werfen (Barcelona, Spain) has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Aptiva Connective Tissue Disease (CTD) Essential reagent. This product complements the company's already FDA-approved Aptiva Celiac Disease reagent. Apart from CTD and Celiac Disease tests, Aptiva is working on diagnostics for other autoimmune conditions and has more than 60 analytes at different stages of advanced development. These analytes have the capability to shorten the diagnostic time for autoimmune diseases and contribute to more effective patient care.

The Aptiva system is a fully automated multi-analyte platform that marks the next generation of high-throughput multi-analyte systems for clinical autoimmune labs. This system employs particle-based multi-analyte technology (PMAT) which simultaneously processes multiple analytes using a single patient sample. Thanks to PMAT, the Aptiva CTD Essential reagent can yield of up to 600 results per hour and enable labs to handle their testing volumes with minimal hands-on time.

"Aptiva CTD Essential with its unique biomarker composition and high level of analytical and clinical performance represents a breakthrough that fundamentally enhances the utility of diagnostic testing in the autoimmune laboratory," said Michael Mahler, PhD, Vice President of Research and Business Development at Werfen. "We are excited to bring this latest expansion of the Aptiva reagent menu to the US market, resulting in advanced patient care."

Related Links:
Werfen 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.